Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 1 2Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Plasma cell 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Crizotinib 2Vindesine 1Vincristine 1Rituximab 1Radiation 1R-CHOP protocol 1Prednisolone 1Methotrexate 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Large-Cell, Anaplastic × Crizotinib × Clear all
NCT05160922 2026-03-30

Crizotinib Continuation Clinical Study

Pfizer

Phase 4 Active not recruiting
27 enrolled
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT02487316 2016-12-30

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Peking University

Phase 4 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡